However, in contrast to our studies, Yi et al. evaluated a combination therapy approach of CDK4/6 and PARP inhibitors in ovarian cancer and observed an increase in apoptosis under these conditions [36]. The gene discussed is PARP1; the disease is ovarian carcinoma.